Lisata Therapeutics
LSTA
Lisata Therapeutics (LSTA) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.49
- EPS estimate
- −$0.54
- EPS surprise
- +8.41%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 6, 2025 | −$0.54 | −$0.49 | +8.41% | $0.00 | SEC |
| Q2 2025 | Aug 7, 2025 | −$0.65 | −$0.54 | +16.92% | $70,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.53 | −$0.55 | −3.77% | $0.00 | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.76 | −$0.55 | +27.63% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.75 | −$0.59 | +21.33% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.75 | −$0.61 | +18.67% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.73 | −$0.65 | +10.34% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.86 | −$0.66 | +22.81% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.93 | −$0.65 | +30.11% | $0.00 | SEC |
| Q2 2023 | Aug 14, 2023 | −$0.70 | −$0.50 | +28.57% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.81 | −$0.77 | +4.94% | $0.00 | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.96 | −$0.76 | +20.83% | $0.00 | SEC |
| Q3 2022 | Nov 10, 2022 | −$1.28 | −$7.88 | −518.04% | $0.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$1.73 | −$1.65 | +4.35% | $0.00 | SEC |
| Q1 2022 | May 5, 2022 | −$1.45 | −$1.05 | +27.59% | $0.00 | SEC |
| Q4 2021 | Mar 22, 2022 | −$1.85 | −$1.65 | +10.81% | $0.00 | SEC |
| Q3 2021 | Nov 4, 2021 | −$1.95 | −$1.80 | +7.69% | $0.00 | SEC |
| Q2 2021 | Aug 5, 2021 | −$2.18 | −$1.50 | +31.03% | $0.00 | SEC |
| Q1 2021 | May 6, 2021 | −$1.13 | −$2.85 | −153.33% | $0.00 | SEC |
| Q4 2020 | Feb 25, 2021 | −$3.98 | −$4.20 | −5.66% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Lisata Therapeutics (LSTA) last report earnings?
Lisata Therapeutics last reported on Nov 6, 2025, covering fiscal Q3 2025.
Did LSTA beat earnings estimates?
Yes. Lisata Therapeutics reported EPS of −$0.49 for Q3 2025 against a −$0.54 estimate — a 8.41% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.